Literature DB >> 24321544

Recurrent Miller Fisher syndrome in children.

Salvatore Grosso1, Alberto Verrotti2, Monica Tei3, Sara Cornacchione3, Fabio Giannini4, Paolo Balestri3.   

Abstract

BACKGROUND: Miller Fisher syndrome is usually a monophasic disorder. Recurrent Miller Fisher syndrome is extremely rare, and all patients with recurrences have been adults. Although the optimal treatment for Miller Fisher syndrome has yet to be established, the typical therapy includes intravenous immunoglobulin or plasma exchange. The efficacy of steroids is still debated. PATIENTS: We describe two children with recurrent Miller Fisher syndrome. Episodes occurred at the age of 11.5 and 13 years in patient 1 and at the age of 8 and 13 years in patient 2.
RESULTS: Clinical patterns of the first and recurrent episodes of Miller Fisher syndrome were overlapping. In both patients, steroids were effective in controlling clinical deterioration of Miller Fisher syndrome recurrences.
CONCLUSIONS: Recurrent Miller Fisher syndrome is a rare disorder that may occur in children. Our observations and a review of the literature suggest that there may be a small group of patients in whom steroids may be a therapeutic option when intravenous immunoglobulin fails to control clinical symptoms.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Guillaine-Barrè syndrome; demyelination; neuroimmunology; pediatrics; steroids

Mesh:

Substances:

Year:  2013        PMID: 24321544     DOI: 10.1016/j.pediatrneurol.2013.10.016

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  2 in total

1.  Late Presentation of Ataxia, Areflexia, and Electrophysiological Abnormalities as Part of Miller Fisher Syndrome: Case Report.

Authors:  Deniz Somer; Arzu Yilmaz; Serap Tiras Teber; Fatma Gul Cinar
Journal:  Neuroophthalmology       Date:  2016-06-08

2.  Miller Fisher Syndrome Mimicking Tolosa-Hunt Syndrome.

Authors:  Masahiro Oomura; Yuto Uchida; Keita Sakurai; Takanari Toyoda; Kenji Okita; Noriyuki Matsukawa
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.